FOLH1 and posterior cortical atrophy: Radioligand therapy (177Lu-PSMA-RLT, 225Ac-PSMA-RLT), antibody–drug conjugates (MLN2704, PSMA-MMAE, MEDI3726), cellular immunotherapy (CAR-T, CAR/NK-92, PSMA-targeted BiTE), PSMA-targeted photodynamic therapy, PSMA-PET, PSMA-targeted RGS, and multimodal PSMA-targeted imaging guided therapy are common PSMA-targeted therapies with encouraging anti-tumor activity in PCa [9].